CorMedix (NASDAQ:CRMD) Stock Rating Cut to “Sell” at Wall Street Zen

CorMedix (NASDAQ:CRMD) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

Other research analysts have also recently issued research reports about the company. Oppenheimer reiterated an “outperform” rating and issued a $13.00 target price (down from $15.00) on shares of CorMedix in a report on Friday. Weiss Ratings lowered CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday. Citigroup reissued a “market outperform” rating on shares of CorMedix in a research report on Tuesday. Royal Bank Of Canada lifted their price target on shares of CorMedix from $14.00 to $15.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, UBS Group set a $19.00 price objective on shares of CorMedix in a research note on Tuesday. Eight analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.22.

CorMedix Trading Down 3.7%

Shares of CRMD opened at $4.66 on Friday. CorMedix has a fifty-two week low of $4.65 and a fifty-two week high of $13.02. The company has a market capitalization of $363.20 million, a PE ratio of 3.75, a price-to-earnings-growth ratio of 0.90 and a beta of 1.48. The stock has a fifty day moving average of $7.18 and a two-hundred day moving average of $7.57. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.36 and a current ratio of 2.56.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.07). CorMedix had a net margin of 15.49% and a return on equity of 27.12%. The business had revenue of $54.52 million during the quarter, compared to analysts’ expectations of $51.76 million. As a group, analysts forecast that CorMedix will post 0.54 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Advisors Asset Management Inc. acquired a new position in CorMedix in the 3rd quarter worth $26,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of CorMedix in the third quarter worth about $31,000. Kestra Advisory Services LLC lifted its stake in shares of CorMedix by 142.9% in the first quarter. Kestra Advisory Services LLC now owns 10,200 shares of the company’s stock worth $69,000 after acquiring an additional 6,000 shares in the last quarter. Quantbot Technologies LP purchased a new position in CorMedix in the second quarter valued at about $85,000. Finally, Allworth Financial LP purchased a new position in CorMedix in the second quarter valued at about $88,000. 34.18% of the stock is currently owned by hedge funds and other institutional investors.

Key CorMedix News

Here’s some of the latest news about CRMD:

• Positive Sentiment: CorMedix reported third-quarter revenue of $54.5 million, above the roughly $51.8 million analyst estimate, and adjusted EBITDA of $3.1 million. The company maintained its 2026 revenue outlook and narrowed its adjusted EBITDA guidance. CorMedix third-quarter results and business update
• Positive Sentiment: The planned Heron asset acquisition could add an estimated $125 million–$150 million in pro forma 2027 revenue, with management targeting $45 million–$60 million in annual synergies. Heron assets and synergy outlook
• Negative Sentiment: DefenCath pricing pressure is weighing on sales expectations, despite the quarterly revenue beat. CorMedix reported a $14.7 million net loss, and coverage described the earnings result as disappointing; progress with Rezzayo and the Heron transaction are part of the company’s longer-term outlook. Zacks coverage of quarterly results and pricing pressure

CorMedix Company Profile

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.